BrightGene Bio Medical Technology C (688166) - Cash Flow Conversion Efficiency

Latest as of June 2023: 0.011x

Based on the latest financial reports, BrightGene Bio Medical Technology C (688166) has a cash flow conversion efficiency ratio of 0.011x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥26.70 Million ≈ $3.91 Million USD) by net assets (CN¥2.35 Billion ≈ $344.34 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

BrightGene Bio Medical Technology C - Cash Flow Conversion Efficiency Trend (2016–2024)

This chart illustrates how BrightGene Bio Medical Technology C's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read BrightGene Bio Medical Technology C (688166) financial obligations for a breakdown of total debt and financial obligations.

BrightGene Bio Medical Technology C Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of BrightGene Bio Medical Technology C ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Victoria's Secret & Co NYSE:VSCO	-0.261x
TSINGTAO BREWE. H ADR/5 F:TSI0	N/A
Cenergy Holdings SA BR:CENER	-0.040x
Zhejiang Dingli Mach Co Ltd SHG:603338	0.032x
Endeavour Group Ltd AU:EDV	0.030x
Jushri Technologies Inc Class A SHE:300762	-0.010x
Munters Group AB ST:MTRS	0.124x
Nordstrom Inc NYSE:JWN	0.786x

Annual Cash Flow Conversion Efficiency for BrightGene Bio Medical Technology C (2016–2024)

The table below shows the annual cash flow conversion efficiency of BrightGene Bio Medical Technology C from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see BrightGene Bio Medical Technology C (688166) market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CN¥2.44 Billion ≈ $356.66 Million	CN¥245.56 Million ≈ $35.93 Million	0.101x	+25.06%
2023-12-31	CN¥2.42 Billion ≈ $353.77 Million	CN¥194.77 Million ≈ $28.50 Million	0.081x	-41.98%
2022-12-31	CN¥2.24 Billion ≈ $328.03 Million	CN¥311.26 Million ≈ $45.55 Million	0.139x	+37.34%
2021-12-31	CN¥1.74 Billion ≈ $254.86 Million	CN¥176.08 Million ≈ $25.77 Million	0.101x	-6.82%
2020-12-31	CN¥1.43 Billion ≈ $209.63 Million	CN¥155.43 Million ≈ $22.74 Million	0.108x	+132.28%
2019-12-31	CN¥1.31 Billion ≈ $192.15 Million	CN¥61.33 Million ≈ $8.98 Million	0.047x	-43.58%
2018-12-31	CN¥772.85 Million ≈ $113.09 Million	CN¥63.99 Million ≈ $9.36 Million	0.083x	+3.25%
2017-12-31	CN¥446.02 Million ≈ $65.27 Million	CN¥35.77 Million ≈ $5.23 Million	0.080x	-40.63%
2016-12-31	CN¥220.15 Million ≈ $32.21 Million	CN¥29.73 Million ≈ $4.35 Million	0.135x	--

About BrightGene Bio Medical Technology C

SHG:688166 China Biotechnology

Market Cap

$4.13 Billion

CN¥28.24 Billion CNY

Market Cap Rank

#4097 Global

#710 in China

Share Price

CN¥66.74

Change (1 day)

+5.77%

52-Week Range

CN¥40.25 - CN¥116.49

All Time High

CN¥116.49